Opaganib Milik RedHill Biopharma Berhasil Mencegah Replikasi SARS-CoV-2 Sepenuhnya
September 10, 2020 19:00 ET
|
RedHill Biopharma Ltd.
Berdasarkan studi inkubasi selama tiga hari dalam model in vitro jaringan bronkial manusia, Opaganib berhasil mencegah replikasi virus SARS-CoV-2 sepenuhnya, sebanding dengan remdesivir sebagai...
研究顯示 RedHill Biopharma 的 Opaganib 可全面抑制 SARS-CoV-2
September 10, 2020 19:00 ET
|
RedHill Biopharma Ltd.
Opaganib 在人類支氣管組織體外模型中培育三天後，其完全抑制 SARS-CoV-2 病毒複製的測量結果比研究的陽性對照 remdesivir 優勝 -- Opaganib 是一種獨特口服潛在 COVID-19 治療藥物，結合有效的抗病毒及抗炎作用機制，針對宿主細胞成分並盡量減少抗藥性 -- 全球第 2/3 期及美國第 2 期臨床研究目前正在使用 opaganib 治療嚴重 COVID-19...
Opaganib von RedHill Biopharma zeigt nachweislich die vollständige Hemmung von SARS-CoV-2
September 10, 2020 04:16 ET
|
RedHill Biopharma Ltd.
Opaganib hemmte die Replikation des SARS-CoV-2-Virus vollständig, gemessen nach dreitägiger Inkubation in einem In-vitro-Modell von menschlichem Bronchialgewebe, wobei ein Vergleich mit Remdesivir,...
L'opaganib de RedHill Biopharma démontre une inhibition complète du SARS-CoV-2
September 10, 2020 04:16 ET
|
RedHill Biopharma Ltd.
L'opaganib inhibe complètement la réplication virale du SARS-CoV-2 telle que mesurée après trois jours d'incubation dans un modèle in vitro de tissu bronchique humain, ce qui le compare favorablement...
Opaganib van RedHill Biopharma laat volledige remming van SARS-CoV-2 zien
September 10, 2020 04:16 ET
|
RedHill Biopharma Ltd.
Opaganib remt de virale replicatie van SARS-CoV-2 volledig, zoals gemeten na drie dagen incubatie in een in-vitro model van humaan bronchiaal weefsel; en kent een gunstige vergelijking met remdesivir,...
Opaganib RedHill Biopharma демонстрирует полное ингибирование SARS-CoV-2
September 10, 2020 00:00 ET
|
RedHill Biopharma Ltd.
Opaganib полностью подавил репликацию вируса SARS-CoV-2, что было измерено после трехдневной инкубации на модели бронхиальной ткани человека in vitro, по сравнению с remdesivir, положительным...
RedHill Biopharma의 opaganib, SARS-CoV-2 완전히 억제하는 것으로 나타나
September 09, 2020 18:00 ET
|
RedHill Biopharma Ltd.
opaganib, 3일간의 인큐베이션 결과 인간 기관지 조직의 in vitro 모델에서 SARS-CoV-2 바이러스 복제 완전히 억제하는 효과가 양성 대조군인 렘데시비르보다 우수-- opaganib, 강력한 항바이러스 및 항염증 작용 기제 결합된 경구용 코로나19 치료제 잠재력 갖춰, 숙주 세포 성분을 타깃으로 하며 내성을 최소화 -- opaganib,...
Opaganib de RedHill Biopharma demuestra inhibición completa de SARS-CoV-2
September 09, 2020 07:52 ET
|
RedHill Biopharma Ltd.
Opaganib inhibió completamente la replicación viral del SARS-CoV-2, según su medición después de tres días de incubación en un modelo in vitro de tejido bronquial humano, comparando favorablemente con...
Opaganib da RedHill Biopharma Demonstra Inibição Completa do SARS-CoV-2
September 09, 2020 07:52 ET
|
RedHill Biopharma Ltd.
O opaganib inibiu completamente a replicação viral do SARS-CoV-2, conforme medido após três dias de incubação em um modelo in vitro de tecido brônquico humano, comparando favoravelmente com...
RedHill to Present at the Morgan Stanley Annual Global Healthcare Conference and Additional September Events
September 09, 2020 07:00 ET
|
RedHill Biopharma Ltd.
TEL AVIV, Israel and RALEIGH, N.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that...